Pioneering perspectives

David Reardon, MD, Dana-Farber Cancer Institute, USA

Portrait of a person in a blue blazer and light shirt against a purple-to-orange gradient background, accompanied by podcast-style microphone icons and circular graphic elements
Portrait of a person in a blue blazer and light shirt against a purple-to-orange gradient background, accompanied by podcast-style microphone icons and circular graphic elements
Logo

Pioneering perspectives

"Our patients are in a race...cancers have a 50- or 100-yard head start...we need to get therapies to the patients as quickly as possible, overcome that head start, and ultimately win the race.”

David Reardon, MD, Dana-Farber Cancer Institute, USA

Further discussion

Racing against time – advancing cell therapies for brain cancer

David Reardon, MD, Clinical Director at the Dana-Farber Cancer Institute and the Boston Center for Neuro-Oncology, has dedicated his career to tackling one of the most complex and devastating diseases in oncology: brain cancer.1-4 Despite the transformative impact of immunotherapy in many cancer types, brain tumors remain largely resistant to these advances due to the unique immune microenvironment of the brain.5-7 Dr. Reardon and his team, however, are determined to change that.

At his center, Dr. Reardon explains in his interview, a wide range of clinical trials are underway to address this unmet medical need. Among the most promising approaches is individualized cell and gene therapy, which offers the potential to tailor treatments to each patient’s unique cancer profile. However, this approach comes with significant challenges. “Each product for each patient is going to have unique features…[they are] very labor intensive and very high-tech dependent," Dr. Reardon explains.

For such approaches treating aggressive brain cancers, however, one of the most critical factors is time. “Our patients are in a race…the cancers have a 50- or 100-yard head start," Dr. Reardon notes. Reducing wait times, incubation periods, and culturing durations without the compromise of product quality is essential. He acknowledges the significant investment Miltenyi Biotec has made in optimizing these processes, making therapy manufacturing processes faster and more robust.

Technological advancement focusing on automation and efficiency is key to directly addressing the importance speed of treatment has for the patient. Dr. Reardon highlights the importance of technologies like the CliniMACS Prodigy® Platform, which enables streamlined manufacturing of personalized therapies by, for example, reducing open handling steps. “Systems like those developed at Miltenyi Biotec are allowing us, for the first time, to really tap into that individualized and personalized approach,” Dr. Reardon explains.

Automation also plays a vital role in minimizing variability and ensuring consistency in manufacturing. This not only improves efficiency but also enhances safety and regulatory confidence – especially important in high-stakes therapies for vulnerable patient populations.

Looking ahead, Dr. Reardon sees enormous potential in combinatorial regimens, where cell therapies are paired with immune checkpoint inhibitors and other modalities. Recent research supports this direction. A 2023 review in the Journal of Translational Medicine highlights the potential of mRNA-based personalized therapies and combinatorial approaches – such as pairing cell therapies with checkpoint inhibitors – to overcome resistance in brain cancer.8 Similarly, a 2025 article in Medical Oncology emphasizes the transformative impact of precision oncology, driven by genomic profiling and individualized treatment strategies.9 These combinations could unlock new treatment paradigms and bring hope to patients who have long faced limited options and harsh side effects from traditional therapies.

By leveraging advanced technologies and collaborative innovation, Dr. Reardon and his team are pushing the boundaries of what’s possible in neuro-oncology – bringing us closer to a future where personalized, effective, and less toxic treatments are within reach for brain cancer patients.

“I think the future for cell and gene therapies is incredibly exciting. I think we have begun to scratch the surface…there's so much potential.”

David Reardon, MD, Dana-Farber Cancer Institute, USA

Watch more interviews